Form 4: Arcutis CMO Patrick Burnett Sells Shares for Tax Coverage

Arcutis Biotherapeutics EVP and Chief Medical Officer Patrick Burnett sold 222 shares of common stock to satisfy tax withholding obligations.

Summary

• Patrick Burnett, EVP and Chief Medical Officer of Arcutis Biotherapeutics, Inc. (ARQT), sold 222 shares of common stock.
• The transaction occurred on May 11, 2026, at a price of $21.05 per share.
• The sale was executed to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
• Following this transaction, the reporting person maintains beneficial ownership of 120,244 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale is purely administrative and related to tax obligations rather than a discretionary divestment.

Positives

• The transaction was routine and non-discretionary, specifically intended to satisfy tax obligations upon RSU vesting.

Negatives

• The sale represents a reduction in the insider's direct equity stake in the company.

Risks

• None identified; this is a standard administrative transaction for tax compliance.

Future Outlook

No forward-looking guidance or strategic outlook provided in this filing.

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

Industry Context

StockSavvy.ai notes that this is a standard 'sell-to-cover' transaction common in the biotechnology sector, where executives frequently sell a portion of vested equity to meet tax liabilities rather than signaling a lack of confidence in the company's future performance.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for executive compensation and tax withholding.
• Similar to practices at other mid-cap biotech firms, executives utilize Rule 10b5-1 plans to manage tax obligations systematically.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and limited in scope.

Next Steps

• None mentioned.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, Insider Trading, Form 4, Biotech, Executive Compensation